Compare Moderna, Inc. (MRNA) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PubMatic Inc — how do they compare? Moderna, Inc. trades at $205.4 (market cap $78.65B), while PubMatic Inc trades at $18.99 (market cap $850.88M). The key difference: Moderna, Inc. is far larger — about 92.4× PubMatic Inc's market cap, and PubMatic Inc is more actively traded (997,698 versus 37,373,437). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and PubMatic Inc for 40 Days on average.
| MRNA | PUBM | |
|---|---|---|
Market Cap | $78.65B | $850.88M |
Volume | 37,373,437 | 997,698 |
Sector | Health | Technology |
52-Week High | $203.46 | $19.18 |
52-Week Low | $22.36 | $6.28 |
Typical Hold Time | 59 Days | 40 Days |
Enterprise Value | $74.80B | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
PubMatic (PUBM) trades at $19.02, up 2.42% with a bullish technical signal and strong analyst consensus. The company shows mixed fundamentals with negative net income margins but positive cash flow and recent earnings beats. Recent Q2 2026 results exceeded expectations with 11% revenue growth, driven by mobile app and CTV segments. Technical indicators show bullish moving averages with neutral oscillators, while support sits at $18 and resistance at $19.
The outlook remains cautiously optimistic with 64.7% analyst buy ratings and a $19.89 price target. Key opportunities include AI-driven ad growth and market share gains, while risks involve persistent profitability challenges and competitive pressures in digital advertising. The CFO's planned retirement adds transitional uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
